Therapeutic antibodies have become one of the most rapidly growing drug classes to treat autoimmune diseases, inflammatory diseases, cancer and COVID-19. However, despite major recent scientific breakthroughs, limitations remain that impede widespread use of antibodies as therapeutics (i.e., limited antibody uptake in the target tissue, antibody retention and immunogenicity).
To overcome these therapeutic challenges, research efforts have led to the development of next-generation antibodies such as bispecific (multispecific) antibodies, nanobodies, antibody drug conjugates, antibody fragments and antibody-like proteins. Next-generation antibodies are designed to be more selective than monoclonal antibodies (mAbs), with the potential to block multiple targets and possibly interact with new targets. This greater target specificity can improve efficacy and potency and reduce unwanted side effects.
With the increasing number and complexity of next-generation antibodies, it is imperative to characterize them thoroughly to optimize existing candidates or design new antibodies with desirable therapeutic properties. Our article collection, Next-Generation Antibody Discovery: Advancing the Development of Targeted Therapeutics, highlights several applications that focus on aspects of antibody characterization.
Through this research article collection, we hope to educate researchers on strategies to characterize antibody candidates and enhance their development and optimization.
What You Will Learn:
Content Includes:
Complete the Form to Download the Article Collection
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.